Browsing Tag
neuromyelitis optica spectrum disorder
5 posts
Amgen (NASDAQ: AMGN) wins EC approval for UPLIZNA in generalized myasthenia gravis market
European Commission clears Amgen Inc.’s UPLIZNA for generalized myasthenia gravis. Discover what this means for competition, pricing, and the autoimmune drug market.
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has…
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca…
US biotech company Viela Bio bags Uplizna FDA approval for NMOSD
Uplizna FDA approval : US biotech company Viela Bio has secured approval from the US Food and Drug…
Alexion Pharmaceuticals secures FDA priority review for SOLIRIS in neuromyelitis optica spectrum disorder
Alexion Pharmaceuticals has secured a significant milestone with the FDA granting priority review for its C5 complement inhibitor,…